BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33539629)

  • 1. Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia.
    von Heydebrand F; Fuchs M; Kunz M; Voelkl S; Kremer AN; Oostendorp RAJ; Wilke J; Leitges M; Egle A; Mackensen A; Lutzny-Geier G
    Stem Cells; 2021 Jun; 39(6):819-830. PubMed ID: 33539629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
    Trimarco V; Ave E; Facco M; Chiodin G; Frezzato F; Martini V; Gattazzo C; Lessi F; Giorgi CA; Visentin A; Castelli M; Severin F; Zambello R; Piazza F; Semenzato G; Trentin L
    Oncotarget; 2015 Dec; 6(39):42130-49. PubMed ID: 26517523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.
    Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Mineur P; Le Roy C; Saint-Georges S; Varin-Blank N; Cymbalista F; Bron D; Lagneaux L
    Haematologica; 2012 Apr; 97(4):608-15. PubMed ID: 22058221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
    Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
    Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.
    Gehrke I; Gandhirajan RK; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
    Mol Med; 2011; 17(7-8):619-27. PubMed ID: 21519633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
    Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
    Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.
    Liu PP; Liu J; Jiang WQ; Carew JS; Ogasawara MA; Pelicano H; Croce CM; Estrov Z; Xu RH; Keating MJ; Huang P
    Oncogene; 2016 Oct; 35(43):5663-5673. PubMed ID: 27065330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune modulatory effects of Idelalisib in stromal cells of chronic lymphocytic leukemia.
    Handl S; von Heydebrand F; Voelkl S; Oostendorp RAJ; Wilke J; Kremer AN; Mackensen A; Lutzny-Geier G
    Leuk Lymphoma; 2021 Nov; 62(11):2679-2689. PubMed ID: 33999745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.
    Vangapandu HV; Ayres ML; Bristow CA; Wierda WG; Keating MJ; Balakrishnan K; Stellrecht CM; Gandhi V
    Neoplasia; 2017 Oct; 19(10):762-771. PubMed ID: 28863345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.
    Martinez Marignac VL; Smith S; Toban N; Bazile M; Aloyz R
    Oncotarget; 2013 Dec; 4(12):2550-66. PubMed ID: 24334291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch.
    Ding W; Knox TR; Tschumper RC; Wu W; Schwager SM; Boysen JC; Jelinek DF; Kay NE
    Blood; 2010 Oct; 116(16):2984-93. PubMed ID: 20606160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.
    Xu J; Zhou P; Wang W; Sun A; Guo F
    J Mol Med (Berl); 2014 Jan; 92(1):77-92. PubMed ID: 24042463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
    Zhang W; Pelicano H; Yin R; Zeng J; Wen T; Ding L; Huang R
    Mol Med Rep; 2015 Nov; 12(5):7374-88. PubMed ID: 26458979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.
    Shehata M; Schnabl S; Demirtas D; Hilgarth M; Hubmann R; Ponath E; Badrnya S; Lehner C; Hoelbl A; Duechler M; Gaiger A; Zielinski C; Schwarzmeier JD; Jaeger U
    Blood; 2010 Oct; 116(14):2513-21. PubMed ID: 20576813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.
    Lutzny G; Kocher T; Schmidt-Supprian M; Rudelius M; Klein-Hitpass L; Finch AJ; Dürig J; Wagner M; Haferlach C; Kohlmann A; Schnittger S; Seifert M; Wanninger S; Zaborsky N; Oostendorp R; Ruland J; Leitges M; Kuhnt T; Schäfer Y; Lampl B; Peschel C; Egle A; Ringshausen I
    Cancer Cell; 2013 Jan; 23(1):77-92. PubMed ID: 23328482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications.
    Crompot E; Van Damme M; Pieters K; Vermeersch M; Perez-Morga D; Mineur P; Maerevoet M; Meuleman N; Bron D; Lagneaux L; Stamatopoulos B
    Haematologica; 2017 Sep; 102(9):1594-1604. PubMed ID: 28596280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.